Bristol Myers Squibb Receives European Commission Approval of CAMZYOS, for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb announces that the European Commission has approved CAMZYOS® for the treatment of symptomatic hypertrophic obstructive cardiomyopathy in adult patients. CAMZYOS is the first and only reversible and allotropic Selective Cardiac Myosin Inhibitor approved in all Member States…